Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 investigator-initiated trial of eftilagimod alpha in conjunction with pembrolizumab plus doublet chemotherapy (carboplatin and pemetrexed) in patients with various solid tuumours

Next Previous
X
Search
Trial Profile

Phase 1 investigator-initiated trial of eftilagimod alpha in conjunction with pembrolizumab plus doublet chemotherapy (carboplatin and pemetrexed) in patients with various solid tuumours

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Eftilagimod alpha (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms INSIGHT-003

    • Most Recent Events

    • 29 Apr 2024 According to an Immutep Limited media release, 38 out of a total of 50 patients have been enrolled and safely dosed across six sites in Germany.
    • 22 Nov 2023 According to an Immutep Limited media release, the extension opened in mid-2023 and 29 patients have been enrolled to date. With the addition of the new sites, the trial is expected to complete recruitment in 1H CY2024.
    • 22 Nov 2023 According to an Immutep Limited media release, the company trial has been expanded to four sites across Germany including the University Clinic of Ruhr Universitat Bochum and the Lung Clinic Cologne-Merheim.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top